Lipitor, Atorvastatin

Lipitor, Atorvastatin Newswire

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic).

Results 1 - 20 of 231 in Lipitor, Atorvastatin (generic)

  1. Drug and medical cost effects of a drug formulary change with...Read the original story

    48 min ago | CiteULike

    Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. Therapeutic interchange interventions are commonly used to manage pharmacy benefit costs.

    Comment?

  2. Cholesterol-lowering statins increase risk of diabetes 46 percent, study saysRead the original story w/Photo

    4 hrs ago | The Oregonian

    A large-scale study indicates that taking cholesterol-lowering statins to reduce the risk of stroke and heart disease could increase the risk developing type 2 diabetes by 46 percent. The authors investigated the effect of taking statins on the risk of developing adult onset diabetes and a decreased ability to control blood sugar.

    Comment?

  3. Statins Raise Diabetes Risk by Nearly 50 PercentRead the original story w/Photo

    5 hrs ago | News Max

    Cholesterol-lowering statin drugs may significantly increase a person's risk of developing type 2 diabetes, a new study from Finland suggests. Researchers found that statins were associated with an almost 50 percent higher risk of developing type 2 diabetes, even after adjusting for other factors.

    Comment?

  4. Statins found to increase risk of diabetesRead the original story

    18 hrs ago | Scotsman.com

    Congratulations, you're now registered! Let us know what news and updates you want to hear about and we'll send them straight to your inbox. RESEARCHERS have found that taking statins to reduce cholesterol increases the risk of developing diabetes by as much as 46 per cent.

    Comment?

  5. Study shows that use of statins increases risk of developing diabetes by 46 percentRead the original story w/Photo

    20 hrs ago | PhysOrg Weblog

    New research published in Diabetologia shows that use of statins is associated with a 46% increase in the risk of developing diabetes, even after adjustment for confounding factors. The study is by Professor Markku Laakso, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Finland, and colleagues.

    Comment?

  6. Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling...Read the original story w/Photo

    21 hrs ago | PRWeb

    The Firm is representing a number of Lipitor lawsuit plaintiffs in federal court, all of whom allegedly developed Type 2 diabetes due to their use of the statin medication. Our Firm is representing a number of Lipitor lawsuit plaintiffs whose claims are currently pending in federal court, and we are pleased to see this litigation progressing.

    Comment?

  7. Pfizer Inc. Has a Growth Problem -- Here Are 3 Ways to Change ThatRead the original story w/Photo

    Yesterday | The Motley Fool

    Pfizer's problems in a nutshell Like much of the big pharmaceutical sector, Pfizer has struggled with the loss of exclusivity on key branded drugs. The patent life on a drug in the United States begins when the Food and Drug Administration approves an investigational new drug application and lasts for 20 years.

    Comment?

  8. It is hard for people to swallow pills they can't affordRead the original story w/Photo

    Monday | Kevin, M.D.

    Cholesterol pills are one of the great medical advances I've witnessed during my professional career. I am talking specifically about a category of medications called statins, drugs like Lipitor and Pravachol.

    Comment?

  9. Pharmacist apologises after giving out wrong medicationRead the original story

    Sunday Mar 1 | The Otago Daily Times

    A woman spent five days in hospital recovering from liver problems caused by being given the wrong medicine by a pharmacist. Deputy Health and Disability Commissioner Theo Baker, who investigated the case, found in a report released today that the pharmacist had breached the code of patients' rights by failing to ensure he dispensed the correct medicine.

    Comment?

  10. Lipitor inventor takes aim at cholesterol againRead the original story w/Photo

    Sunday Mar 1 | The Day

    Detroit - The scientist widely credited with co-discovering the best-selling drug in U.S. history - cholesterol-lowering Lipitor - is quietly back at it. After reviving Esperion Therapeutics in 2008 - just a year after Pfizer had closed the first version of the biotech company - Roger Newton is once again taking aim at cholesterol.

    Comment?

  11. Federal Lipitor Litigation Issues New Order Pertaining to Discovery in...Read the original story w/Photo

    Friday Feb 27 | PRWeb

    The Firm is representing numerous Lipitor lawsuits plaintiffs in the federal litigation, and bellwether trials may provide insight into jury decisions in similar claims involving allegations that Lipitor increase the risk for Type 2 diabetes. Our Firm is representing numerous Lipitor lawsuit plaintiffs in this litigation who put forth similar allegations regarding the use of the statin medication and diabetes.

    Comment?

  12. Court dismisses case accusing Pfizer Australia of anti-competitive conductRead the original story w/Photo

    Wednesday Feb 25 | Business News

    The federal court has dismissed a case against Pfizer Australia which claimed the pharmaceutical giant misused its market power and engaged in anti-competitive conduct in the way it supplied one of its blockbuster drugs to pharmacists. In January 2012 Pfizer began offering heavy discounts and rebates to pharmacists for its brand-name statin, Lipitor, on the condition the pharmacy also buy a minimum 12 months' supply of Pfizer's cheaper generic version of the same drug.

    Comment?

  13. Statins advocates distorted statistics and downplayed side-effects say expertsRead the original story w/Photo

    Saturday Feb 21 | Daily Mail

    But now experts say the drugs are not as safe or as effective at preventing heart attacks as patients have been led to believe over last 20 years They say the cholesterol-lowering medicines - hailed as miracle drugs when they hit the market 20 years ago - are not as safe or effective at preventing heart attacks as patients have been led to believe. Although they can dramatically cut cholesterol levels, they have 'failed to substantially improve cardiovascular outcomes', says an analysis of data in clinical trials.

    Comment?

  14. Efficacy, Safety Of Statins Exaggerated, Finds ReviewRead the original story

    Saturday Feb 21 | Scientific Blogging

    Statins, cholesterol-lowering drugs prescribed to prevent heart attacks for the last two decades, are not as effective nor as safe as claimed, according to a review by Dr. David M. Diamond, a psychologist at the University of South Florida, and Dr. Uffe Ravnskov, an independent researcher. According to Diamond and Ravnskov, statins produce a dramatic reduction in cholesterol levels, but they have "failed to substantially improve cardiovascular outcomes."

    Comment?

  15. Pssst... Pfizer Just Told Investors That This is the Next Big ThingRead the original story w/Photo

    Saturday Feb 21 | The Motley Fool

    Pfizer's vote of confidence in biosimilars -- the generic alternatives to biologic-based medicines such as AbbVie 's megablockbuster drug Humira -- isn't misplaced. According to Frost & Sullivan, the biosimilar market is expected to surge from just $172 million in 2010 to more than $4 billion in 2017.

    Comment?

  16. Lipitor Lawsuit Attorneys at Bernstein Liebhard LLP Comment on...Read the original story w/Photo

    Saturday Feb 21 | PRWeb

    More Than 1,800 Lipitor lawsuits that allege the cholesterol-lowering statin increases the risk for diabetes have been filed in the U.S. District Court, District of South Carolina Since the Multidistrict Litigation Was Established in February 2014. Lipitor lawsuits alleging the cholesterol-lowering statin is associated with an increased risk of new-onset Type 2 diabetes continue to mount in a federal multidistrict litigation now underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports.

    Comment?

  17. New Sanofi CEO brought Lipitor to marketRead the original story w/Photo

    Friday Feb 20 | Boston.com

    Olivier Brandicourt, whose track record includes the introduction of the best-selling drug in history, takes the helm at Sanofi with the mandate of bringing new drugs to the US after missteps led to his predecessor's ouster. Brandicourt, the 59-year-old head of Bayer AG's health-care division, is "a very good fit" for Sanofi and "has the experience of the portfolio businesses we have," Sanofi's Chairman Serge Weinberg said in an interview.

    Comment?

  18. 6 predictions for cardiology in 2015Read the original story w/Photo

    Thursday Feb 19 | Philly.com

    What will be the top cardiac stories in 2015? It is always hard to predict the future, but here is my spin on what might happen over the next 12 months in the field of cardiology. 1. For the first time in 15 years, a new drug to treat congestive heart failure may come to market in the US.

    Comment?

  19. CVS urges cost controls for new cholesterol drugsRead the original story w/Photo

    Wednesday Feb 18 | Fox News

    CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system "if rigid cost control mechanisms are not put in place." Two of the new injectable cholesterol treatments, called PCSK9 inhibitors, could gain U.S. approval this summer.

    Comment?

  20. UPDATE 2-CVS urges cost controls for new cholesterol drugsRead the original story

    Tuesday Feb 17 | Reuters

    CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system "if rigid cost control mechanisms are not put in place." Two of the new injectable cholesterol treatments, called PCSK9 inhibitors, could gain U.S. approval this summer.

    Comment?